Investigating the weaknesses in small cell lung cancer to develop new treatments
Understanding and targeting unique vulnerabilities governing G1/S transition and replication stress in small cell lung cancer
This study is looking at small cell lung cancer to understand how a protein called LMNA affects the cancer cells and causes problems with their DNA, with the hope of finding new ways to treat patients more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11236017 on NIH RePORTER |
What this research studies
This research focuses on small cell lung cancer (SCLC), a highly aggressive form of cancer with a poor prognosis. The study aims to understand the mechanisms behind increased replication stress in SCLC cells, particularly the role of a protein called LMNA. By exploring how low levels of LMNA contribute to DNA damage and genomic instability, the researchers hope to identify new therapeutic targets. The approach includes using specific agents to stabilize R-loops and inhibit LMNA, potentially leading to more effective treatments for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with small cell lung cancer, particularly those with advanced disease.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that significantly improve survival rates for patients with small cell lung cancer.
How similar studies have performed: Previous research has shown promise in targeting replication stress in cancer, suggesting that this approach may yield beneficial results.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Schultz, Christopher William — Temple Univ of the Commonwealth
- Study coordinator: Schultz, Christopher William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.